Evidence-based Medicine Center, Chung Shan Medical University Hospital, Taichung, Taiwan.
Eur Rev Med Pharmacol Sci. 2023 Dec;27(24):12088-12102. doi: 10.26355/eurrev_202312_34807.
Janus Kinase (JAK) inhibitors have been extensively evaluated for their potential in the management of various diseases. Despite previous research on this topic, there is a lack of bibliometric analysis that summarizes research trends on JAK inhibitors. This study aims to provide a comprehensive overview of the top 100 most frequently cited studies on JAK inhibitors over the last ten years.
The Web of Science database was used to screen and extract relevant studies on JAK inhibitors. The top 100 studies most cited within the JAK inhibitor-related research were identified and evaluated, and various data such as the year of publication, study focus and keywords, author information, and number of citations were extracted and analyzed for further examination.
In the top 100 most cited studies of JAK inhibitors, more than 70% of studies focused on the role of JAK inhibitors in disease treatments, with 42% of these studies focused on using JAK inhibitors as treatment for autoimmune diseases and 19 of them focused on the treatment of neoplasms. Time trend analysis revealed that the keywords "tofacitinib", "atopic dermatitis", and "rheumatoid arthritis" were widely mentioned in 2016, while new trends emerged in 2018, with "ruxolitinib" and "baricitinib" being more commonly mentioned.
The top 100 most frequently cited studies on JAK inhibitors focused primarily on the safety and efficacy of these inhibitors in the management of various diseases, particularly inflammatory diseases and neoplasms. The results can serve as a valuable reference for rheumatologists and immunologists interested in the development of JAK inhibitors and expanding future research fields.
Janus 激酶 (JAK) 抑制剂已广泛评估其在各种疾病管理中的潜力。尽管之前对该主题进行了研究，但缺乏文献计量分析来总结 JAK 抑制剂的研究趋势。本研究旨在提供过去十年中 JAK 抑制剂研究的前 100 篇最常被引研究的综合概述。
使用 Web of Science 数据库筛选和提取 JAK 抑制剂相关研究。确定并评估了 JAK 抑制剂相关研究中被引用次数最多的前 100 篇研究，并提取和分析了各种数据，如发表年份、研究重点和关键词、作者信息以及引用次数等，以进行进一步检查。
在 JAK 抑制剂的前 100 篇最常被引研究中，超过 70%的研究侧重于 JAK 抑制剂在疾病治疗中的作用，其中 42%的研究集中在使用 JAK 抑制剂作为自身免疫性疾病的治疗方法，19 项研究集中在肿瘤的治疗上。时间趋势分析表明，2016 年广泛提到了“托法替尼”、“特应性皮炎”和“类风湿关节炎”等关键词，而 2018 年出现了新的趋势，“鲁索替尼”和“巴瑞替尼”更为常见。
JAK 抑制剂前 100 篇最常被引研究主要集中在这些抑制剂在管理各种疾病（特别是炎症性疾病和肿瘤）中的安全性和疗效上。研究结果可为对 JAK 抑制剂的发展和扩展未来研究领域感兴趣的风湿病学家和免疫学家提供有价值的参考。
